close

Enter

Log in using OpenID

Human Insulin Market

embed
According to a new market report published by Persistence Market Research “Global Market Study on Human Insulin: Asia Pacific to Witness fastest Growth by 2020,” the global human insulin market was valued at USD 24,332.6 million in 2014 and was expe
Human Insulin Market to Extent an Assessed Value of US$49,197.3 million in 2020
According to a new market report published by Persistence Market Research “Global
Market Study on Human Insulin: Asia Pacific to Witness fastest Growth by 2020,” the
global human insulin market was valued at USD 24,332.6 million in 2014 and was expected
to grow at a CAGR of 12.4% from 2014 to 2020, to reach an estimated value of USD
49,197.3 million in 2020.
Globally, the human insulin market is witnessing significant growth due to increasing
prevalence of diabetes and increasing awareness among people about diabetes care. In
addition, technological advancements in insulin delivery devices and increasing prevalence
of lifestyle related disorders such as obesity are also driving the growth of the market.
However, uneven pricing and limited access to human insulin in emerging countries such as
Brazil, India, and China are inhibiting the growth of the human insulin market. In addition,
strict regulatory requirements for drug approval are also restraining the growth of the
market. The global human insulin market was anticipated to grow from an estimated USD
24,332.6 million in 2014 to USD 49,197.3 million in 2020 at a CAGR of 12.4% during the
forecast period.
In North America, increasing prevalence of diabetes with growing age and availability of
advanced human insulin infusion devices are driving the use of human insulin in the market.
View Full Report TOC, Figures and Tables @
https://www.persistencemarketresearch.com/market-research/human-insulin-market/toc
In addition, increasing prevalence of lifestyle associated disorders such as obesity is also
boosting the growth of the human insulin market in this region. For instance, according to
the Centers for Diseases Control and Prevention (CDC), a U.S.-based national public health
institute, over one-third children and adolescents were obese in 2012 in the U.S.
In Europe, the human insulin market is driven by rising aging population and increasing
prevalence of diabetes. In addition, in Germany the market is evolving due to rising
prevalence of diabetes and increasing awareness among people about diabetes care.
However, in Asia-Pacific the growth for human insulin is much higher than developed
countries due to increasing prevalence of diabetes and increasing government initiatives for
improving healthcare.
Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao
Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt, Julphar,
Bristol-Myers Squibb Company, GlaxoSmithKline Plc and Oramed Pharmaceuticals, Inc.
are some of the major players in human insulin market.
Browse Report Overview @
https://www.persistencemarketresearch.com/market-research/human-insulin-market.asp
Author
ashutosh
ashutosh164   documents Email
Document
Category
Health and Medicine
Views
15
File Size
33 KB
Tags
market, Human Insulin Market
1/--pages
Report inappropriate content